ETNB Stock Price, 89bio Inc Quote, Chart

Market Summary

USD8.710.00

Market Closed

0.00%

ETNB Stock Price

View Fullscreen

ETNB RSI Chart

ETNB Valuation

Market Cap

856.9M

Price/Earnings (Trailing)

-5.19

Price/Sales (Trailing)

414.63

EV/EBITDA

-4.2

Price/Free Cashflow

-6.17

ETNB Price/Sales (Trailing)

ETNB Profitability

EBT Margin

-7443.16%

Return on Equity

-32.33%

Return on Assets

-28.59%

Free Cashflow Yield

-16.2%

ETNB Fundamentals

ETNB Revenue

Revenue (TTM)

2.2M

ETNB Earnings

Earnings (TTM)

-165.0M

Earnings Growth (Yr)

-79.22%

Earnings Growth (Qtr)

-28.45%

Breaking Down ETNB Revenue

Last 7 days

-9.2%

Last 30 days

-11.3%

Last 90 days

-1.6%

Trailing 12 Months

-51.3%

How does ETNB drawdown profile look like?

ETNB Financial Health

Current Ratio

15.03

Debt/Equity

0.05

Debt/Cashflow

-6.02

ETNB Investor Care

Shares Dilution (1Y)

35.02%

Diluted EPS (TTM)

-2.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	652.0K	1.2M	1.7M	2.2M
2021	0	0	0	148.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 89bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	ra capital management, l.p.	acquired	7,500,000	5.325	1,408,450	-
Apr 01, 2024	palekar rohan	sold	-575,153	10.91	-52,718	chief executive officer
Apr 01, 2024	palekar rohan	acquired	48,250	1.93	25,000	chief executive officer
Mar 04, 2024	ra capital management, l.p.	bought	20,722,500	15.35	1,350,000	-
Feb 26, 2024	palekar rohan	sold	-48,172	10.76	-4,477	chief executive officer
Feb 17, 2024	mansbach harry h	sold (taxes)	-10,188	9.74	-1,046	chief medical officer
Feb 17, 2024	martins ryan	sold (taxes)	-7,577	9.74	-778	chief financial officer
Feb 17, 2024	le-nguyen quoc	sold (taxes)	-10,188	9.74	-1,046	see remarks
Feb 17, 2024	palekar rohan	sold (taxes)	-44,823	9.74	-4,602	chief executive officer
Feb 09, 2024	palekar rohan	sold (taxes)	-107,062	8.45	-12,670	chief executive officer

Which funds bought or sold ETNB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	BlackRock Inc.	added	21.7	16,342,800	77,266,100	-%
May 10, 2024	CREDIT SUISSE AG/	added	5.75	64,752	699,599	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	18.24	222,618	1,181,620	-%
May 10, 2024	AJOVista, LLC	sold off	-100	-42,323	-	-%
May 10, 2024	WESTFIELD CAPITAL MANAGEMENT CO LP	added	22.88	5,518,650	25,190,700	0.13%
May 10, 2024	CITIGROUP INC	added	94.9	2,471,430	4,868,540	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	24,979	24,979	-%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-69.43	-1,514,210	707,864	-%
May 10, 2024	OSAIC HOLDINGS, INC.	added	8.15	16,927	150,156	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	13.55	30,216	195,086	-%

Are Funds Buying or Selling ETNB?

Are funds buying ETNB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ETNB

No. of Funds

Unveiling 89bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	ra capital management, l.p.	14.8%	14,254,298	SC 13D/A
Feb 14, 2024	deep track capital, lp	2.10%	2e+06	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	4.2%	3,973,784	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	6.0%	5,578,931	SC 13G
Feb 13, 2024	suvretta capital management, llc	5.2%	4,888,434	SC 13G/A
Feb 12, 2024	janus henderson group plc	10.8%	10,081,258	SC 13G/A
Feb 12, 2024	janus henderson group plc	9.6%	8,915,141	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	4.48%	4,225,000	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	5,454,196	SC 13G

Recent SEC filings of 89bio Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
Apr 23, 2024	3	Insider Trading
Apr 19, 2024	ARS	ARS
Apr 17, 2024	8-K	Current Report
Apr 17, 2024	DEF 14A	DEF 14A
Apr 17, 2024	DEFA14A	DEFA14A
Apr 15, 2024	4	Insider Trading
Apr 10, 2024	8-K	Current Report

Peers (Alternatives to 89bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

89bio Inc News

Latest updates

89bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Operating Expenses	-6.2%	25,362,000	27,041,000	24,738,000	25,108,000	26,241,000
S&GA Expenses	30.0%	6,298,000	4,844,000	5,052,000	5,259,000	5,262,000
R&D Expenses	-14.1%	19,064,000	22,197,000	19,686,000	19,849,000	20,979,000
EBITDA Margin	25.6%	-46.22	-62.12	-90.51	-153	-604
Interest Expenses	1.9%	545,000	535,000	434,000	408,000	-
Income Taxes	700.0%	16,000	2,000	-	1,000	-
Earnings Before Taxes	8.3%	-24,586,000	-26,803,000	-25,054,000	-25,564,000	-26,435,000
EBT Margin	24.7%	-47.14	-62.56	-91.16	-154	-609
Net Income	8.2%	-24,602,000	-26,805,000	-25,054,000	-25,565,000	-26,288,000
Net Income Margin	24.5%	-47.15	-62.48	-91.03	-154	-608
Free Cashflow	-82.9%	-27,098,000	-14,815,000	-14,834,000	-24,350,000	-28,267,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-3.2%	577	596	460	493	494	197	201	148	136	162	168	182	199	211	223	77.00	88.00	96.00	18.00	11.00
Current Assets	-3.2%	575	594	460	492	494	196	200	147	135	162	167	181	198	210	223	75.00	87.00	95.00	17.00	11.00
Cash Equivalents	-31.2%	218	316	252	245	351	55.00	72.00	61.00	55.00	52.00	40.00	36.00	68.00	98.00	142	68.00	86.00	93.00	16.00	11.00
Net PPE	-19.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	11.4%	67.00	60.00	50.00	51.00	48.00	45.00	48.00	67.00	33.00	36.00	21.00	9.00	-	8.00	-	-	-	-	-	-
Current Liabilities	29.1%	38.00	30.00	25.00	26.00	24.00	25.00	34.00	27.00	18.00	20.00	20.00	8.00	8.00	8.00	9.00	7.00	8.00	6.00	23.00	4.00
Long Term Debt	-7.0%	23.00	25.00	25.00	24.00	24.00	20.00	13.00	12.00	14.00	17.00	1.00	1.00	-	-	-	-	-	-	-	-
LT Debt, Current	-	2.00	-	-	-	-	-	7.00	8.00	5.00	3.00	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	25.00	25.00	24.00	24.00	20.00	13.00	12.00	14.00	17.00	1.00	1.00	-	-	-	-	-	-	-	-
Shareholder's Equity	-4.8%	511	536	410	442	446	152	153	80.00	103	126	147	173	190	203	214	70.00	80.00	90.00	-	-
Retained Earnings	-11.3%	-509	-457	-417	-382	-344	-315	-290	-263	-238	-213	-186	-158	-137	-123	-110	-95.91	-84.14	-73.60	-54.31	-16.18
Additional Paid-In Capital	-100.0%	-	993	828	825	790	467	444	344	342	339	334	331	328	326	325	166	164	164	0.00	0.00
Shares Outstanding	2.1%	95.00	93.00	76.00	74.00	53.00	51.00	29.00	20.00	20.00	20.00	20.00	20.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,176	-	-	-	30.00	-	-	-	166	-	-	-	72,707,052	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-15.8%	-39,720	-34,293	-30,361	-34,447	-30,085	-27,096	-14,815	-14,835	-24,344	-28,240	-13,450	-20,109	-14,982	-14,028	-12,940	-11,524	-7,752	-11,132	-6,197	-3,964	-4,167
Share Based Compensation	23.8%	4,998	4,037	4,381	4,137	3,551	2,758	2,500	2,586	2,512	2,154	2,314	2,417	1,793	1,250	1,154	910	493	166	112	76.00	35.00
Cashflow From Investing	-25.5%	-79,898	-63,643	38,326	-101,808	4,106	-11,061	-42,058	-7,596	26,772	19,086	17,359	-13,876	-15,410	-29,028	-71,999	-5,744	-61.00	-111	-8.00	-18.00	-2.00
Cashflow From Financing	-87.0%	21,030	162,171	-1,480	30,766	321,654	21,011	68,631	28,160	29.00	21,891	72.00	1,692	216	-312	158,292	-65.00	9.00	88,377	488	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ETNB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 47,428	$ 22,306
General and administrative	9,849	6,218
Total operating expenses	57,277	28,524
Loss from operations	(57,277)	(28,524)
Interest expense	(863)	(2,075)
Interest income and other, net	6,556	1,763
Net loss before income tax	(51,584)	(28,836)
Income tax expense	(97)	0
Net loss	(51,681)	(28,836)
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities	(714)	114
Foreign currency translation adjustments	5	(4)
Total other comprehensive (loss) income	(709)	110
Comprehensive loss	$ (52,390)	$ (28,726)
Net loss per share, basic	$ (0.54)	$ (0.54)
Net loss per share, diluted	$ (0.54)	$ (0.54)
Weighted-average shares used to compute net loss per share, basic	95,846,740	53,171,370
Weighted-average shares used to compute net loss per share, diluted	95,846,740	53,171,370

ETNB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 217,573	$ 316,161
Marketable securities	344,715	262,709
Prepaid and other current assets	12,494	14,664
Total current assets	574,782	593,534
Operating lease right-of-use assets	2,118	2,293
Property and equipment, net	37	46
Other assets	385	396
Total assets	577,322	596,269
Current liabilities:
Accounts payable	15,352	8,585
Accrued expenses	20,295	20,530
Operating lease liabilities, current	702	496
Term loan, current	1,892	0
Total current liabilities	38,241	29,611
Operating lease liability, non-current	1,640	1,817
Term loan, noncurrent, net	23,065	24,795
Other noncurrent liabilities	3,837	3,740
Total liabilities	66,783	59,963
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.001 par value: 200,000,000 shares authorized; 95,199,724 and 93,269,377 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	95	93
Additional paid-in capital	1,020,076	993,455
Accumulated other comprehensive (loss) income	(519)	190
Accumulated deficit	(509,113)	(457,432)
Total stockholders’ equity	510,539	536,306
Total liabilities and stockholders’ equity	$ 577,322	$ 596,269

About 89bio Inc

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

CEO	Mr. Rohan Palekar
WEBSITE	89bio.com
INDUSTRY	Biotechnology
EMPLOYEES	45

89bio Inc Frequently Asked Questions

What is the ticker symbol for 89bio Inc? What does ETNB stand for in stocks?

ETNB is the stock ticker symbol of 89bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 89bio Inc (ETNB)?

As of Mon May 13 2024, market cap of 89bio Inc is 856.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ETNB stock?

You can check ETNB's fair value in chart for subscribers.

What is the fair value of ETNB stock?

You can check ETNB's fair value in chart for subscribers. The fair value of 89bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 89bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ETNB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 89bio Inc a good stock to buy?

The fair value guage provides a quick view whether ETNB is over valued or under valued. Whether 89bio Inc is cheap or expensive depends on the assumptions which impact 89bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ETNB.

What is 89bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ETNB's PE ratio (Price to Earnings) is -5.19 and Price to Sales (PS) ratio is 414.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ETNB PE ratio will change depending on the future growth rate expectations of investors.